T he prevalence of heart failure is approximately 1% to 2% of the adult population in developed countries. 1, 2) A major heart failure etiology is left heart disease (LHD), which causes a passive transmission of filling pressure from the left atrium to the pulmonary vessels. Elevated left ventricular end-diastolic pressure plays a key role in the development of pulmonary hypertension in LHD. Furthermore, pulmonary hypertension is common in and has a negative impact on patients with LHD. 3) Liver fibrosis is caused by reduced arterial perfusion and venous congestion, and is associated with mortality in heart failure patients. 4, 5) Liver fibrosis is evaluated by a liver biopsy, which is the gold standard for fibrosis assessment. However, liver biopsies are invasive, and there is a risk of complications. Ultrasound, computed tomography, and magnetic resonance imaging are also used for liver fibrosis evaluation. 6) Other evaluations for liver fibrosis are clinical risk calculators such as the Fibro test, the aspartate aminotransferase-to-platelet ratio, the aspartate aminotransferase/alanine aminotransferase ratio, the Forns index, and the fibrosis-4 index. [7] [8] [9] [10] [11] However, these parameters relating to liver function have not been fully investigated in patients with pulmonary hypertension due to LHD (PH-LHD).
The fibrosis-4 index was originally developed as a non-invasive tool for assessing liver fibrosis in nonalcoholic fatty liver disease, which is confirmed by histopathology. 11) In heart failure patients, centrilobular congestion, necrosis, inflammation, sclerosis, fibrosis, and regenerative hyperplasia are pathologically confirmed. [12] [13] [14] The fibrosis-4 index has been reported to be useful for predicting prognosis in patients with heart failure. 11, 15) PH-LHD causes more severe symptoms and a worse prognostic impact, compared with left-sided heart failure with normal pulmonary artery pressure. 16) Liver dysfunction might lead to increased mortality in patients with PH-LHD. We hypothesized that the fibrosis-4 index, a simple liver fibrosis marker, would have a clinical impact on patients with PH-LHD. Thus, we investigated the characteristics and prognostic value of the fibrosis-4 index in pa- Figure 1 . Algorithm for patient selection. A total of 230 patients with PH-LHD were selected from among 2,540 patients who had undergone RHC. CTEPH indicates chronic thromboembolic pulmonary hypertension; CTD-PH, connective tissue disease-associated pulmonary hypertension; IPAH, idiopathic pulmonary arterial hypertension; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PH-LHD, pulmonary hypertension due to left heart disease; and RHC, right heart catheterization. tients with PH-LHD.
Methods

Study population:
This prospective study included consecutive 253 hospitalized patients who had been newly diagnosed as having PH-LHD, out of a total of 2,540 patients who had undergone right heart catheterization between January 2006 and June 2015 at Fukushima Medical University Hospital. PH-LHD was defined as a mean pulmonary artery pressure of !25 mmHg and a mean pulmonary artery wedge pressure of >15 mmHg according to the 2015 European Society of Cardiology guidelines. 17) Cases of acute coronary syndrome, acute decompensated heart failure, idiopathic pulmonary arterial hypertension, connective tissue disease-related pulmonary hypertension, lung disease, and chronic thromboembolic pulmonary hypertension were excluded. All patients underwent testing for hepatitis B antigen and hepatitis C antibody, and their medical history was checked for chronic liver disease. Of the 253 patients, 23 were excluded; 22 due to liver disease (hepatitis C antibody positive, hepatitis B antigen positive, and other liver diseases including hepatic tumors, fatty liver, alcoholic liver disease, and cirrhosis) and one who did not make follow-up visits, according to their medical records. Finally, 230 patients were enrolled in the current study. Figure 1 shows the enrollment flow chart of the study population. The study protocol was approved by the Institutional Ethics Committee of Fukushima Medical University, and written informed consent was obtained from all patients. Study protocol: Baseline data of age, sex, World Health Organization (WHO) functional class, past medical history, laboratory data, echocardiographic data, and current medications were collected at the time of enrollment. Laboratory data was obtained within one week of right heart catheterization.
As previously described, the fibrosis-4 index was defined as follows: 18) [aspartate transaminase (U/L) × age]/[alanine transaminase 1/2 (U/L) × platelet count (10 9 /L)].
Anemia was defined as hemoglobin values of < 12.0 g/dL in females and < 13.0 g/dL in males. Chronic kidney disease was defined as an estimated glomerular filtration rate of < 60 mL/minute/1.73 m 2 . Hyperuricemia was defined as the usage of antihyperuricemic agents, or serum uric acid levels of > 7 mg/dL. The endpoint was defined as cardiac death and all-cause mortality. We evaluated the characteristics and prognosis associated with the fibrosis-4 index in PH-LHD patients. Hemodynamic measurements: Right heart catheterization was performed for the evaluation of hemodynamic status in the compensated phase initiating heart failure treatment such as oral beta-blockers, angiotensinconverting enzyme-inhibitors, and angiotensin II receptor blockers. Pulmonary artery wedge pressure, pulmonary artery pressure, right atrial pressure, and cardiac index were measured using a 7 Fr Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA, USA). We primarily used the thermos dilution method for the measurement of cardiac output; however, for cases of advanced tricuspid regurgitation, we used the Fick method. Pulmonary vascular resistance was calculated using the conventional formula. Echocardiography: Transthoracic echocardiography was performed by an experienced echocardiographer using standard techniques. 19) The echocardiographic parameters investigated included the left ventricular diastolic diameter The Kaplan-Meier method was used for presenting the event-free rate, and the log-rank test was used for comparisons. To assess the potential heterogeneity of associations between the fibrosis-4 index and cardiac death as well as all-cause mortality, we conducted subgroup analyses. Interactions between the fibrosis-4 index and clinically relevant variables and/or possible confounding factors, including elderly age (< 75 years and !75 years), sex (male and female), presence of WHO classification III or IV, etiology (valvular, ischemia, cardiomyopathy, and others), anemia, chronic kidney disease, hyperuricemia, cardiac index (mean, < 2.2 L/minute/m 2 and !2.2 L/minute/m 2 ), pulmonary vascular resistance (mean, < 2.6 wood unit and ! 2.6 wood unit), mean right atrial pressure (mean, < 10 mmHg and !10 mmHg), diastolic pressure gradient (mean, < 2 mmHg and !2 mmHg), and right ventricular fractional area change (mean, < 39% and ! 39%) were estimated using a Cox proportional hazard model. A P value of < 0.05 was considered statistically significant.
Results
The mean age of the 230 patients was 63.7 ± 14.9 years and 55.2% were male. The fibrosis-4 index ranged from 0.335 to 14.339 (median, 1.909). To compare the characteristics and prognosis associated with the fibrosis-4 index, we divided the patients into the following 3 tertiles, based on their fibrosis-4 index: the first tertile was 0.335 to 1.381; the second tertile was 1.391 to 2.311; and the third tertile was 2.323 to 14.339. Table I compares the baseline characteristics of the patients according to the tertiles. Significant differences were observed among the tertiles, as shown in Table I . Compared with the first tertile, the third tertile was older, more likely to have valvular heart disease, and had higher aspartate transaminase and left ventricular ejection fraction levels. Patients in the third tertile were less likely to have atrial fibrillation, ischemic heart disease, and cardiomyopathy, and had lower estimated glomerular filtration rate, hemoglobin, platelet count, alanine transaminase, albumin, and left ventricular systolic diameter, and used less angiotensinconverting enzyme inhibitors or angiotensin receptor blockers.
PH-LHD patients with valvular heart disease (n = 70, median value of fibrosis-4 index was 2.242) had a significantly higher fibrosis-4 index than PH-LHD patients with non-valvular heart disease (n = 160, median value of fibrosis-4 index was 1.752, P < 0.001).
Regarding hemodynamic variables, there were no significant differences regarding cardiac index, mean pulmonary artery pressure, mean pulmonary artery wedge pressure, pulmonary vascular resistance, transpulmonary pressure gradient, diastolic pressure gradient, or mean right atrial pressure among the 3 tertiles.
During the follow-up period (mean, 1112 ± 822 days), there were 45 deaths (21 cardiac deaths and 24 non-cardiac deaths). As shown in Figure 2 , the survival rate was significantly lower in the third tertile than in the first. Nine patients in the first tertile died: 6 cardiac deaths and 3 non-cardiac deaths. Four of the deaths were from heart failure, and the remaining 5 were due to sudden death, ventricular fibrillation, cerebral hemorrhage, infection, and gastrointestinal bleeding. Fourteen patients in the second tertile died: 5 cardiac deaths and 9 non-cardiac deaths. Of those deaths, 4 were from heart failure, 3 were from infection, 2 were from cancer, and one each from sudden death, multiple organ failure, alveolar hemorrhage, and burns. One was due to an unknown cause. Twentytwo patients in the third tertile died: 10 cardiac deaths and 12 non-cardiac deaths. Of those deaths, 6 were from heart failure, 3 from infection, 2 from cardiopulmonary arrest, 2 from cancer, and one each from sudden death, ventricular tachycardia, amyloidosis, multiple organ failure, suicide, brain hemorrhage, and gastrointestinal bleeding. Two deaths were due to unknown causes. No patient in the current study died due to a liver disease.
In the univariate Cox proportional hazard model, the fibrosis-4 index was a predictor of cardiac death (HR 1.209, 95% CI 1.048-1.395, P = 0.009) and all-cause mortality (HR 1.212, 95% CI 1.099-1.337, P < 0.001) in the PH-LHD patients. Supplemental Table I and Table II show the associations between the fibrosis-4 index and both cardiac death and all-cause mortality in the subgroups after adjustment for interactions between the fibrosis-4 index and clinically important variables (age, sex, WHO classification, etiology, anemia, chronic kidney disease, hyperuricemia, cardiac index, pulmonary vascular resistance, mean right atrial pressure, diastolic pressure gradient, and right ventricular fractional area change). There were no interactions between the index and the variables that affected cardiac death and all-cause mortality.
In addition, we separately analyzed isolated postcapillary pulmonary hypertension (Ipc-PH), and combined postcapillary and precapillary pulmonary hypertension (Cpc-PH) based on the current guidelines. 17) We defined Ipc-PH subgroup (n = 165) as pulmonary vascular resistance !3 wood units and diastolic pressure gradient < 7 mmHg, and Cpc-PH subgroup (n = 65) as pulmonary vascular resistance > 3 wood units and/or diastolic pressure gradient "7 mmHg. The fibrosis-4 index ranged from 0.335 to 14.339 (median, 1.875) in the Ipc-PH subgroup and 0.655 to 6.248 (median, 1.941) in the Cpc-PH subgroup. There were no differences in the fibrosis-4 index between the Ipc-PH and Cpc-PH subgroups (P = 0.704). Supplemental Tables show information on the low and  high fibrosis-4 index groups based on the median fibrosis-4 index. In the Ipc-PH subgroup only, there were significant differences between the high and low fibrosis-4 index groups in valvular heart disease, ischemic heart disease, anemia, atrial fibrillation, aspartate transaminase, left ven-tricular diastolic diameter, left ventricular systolic diameter, and left ventricular ejection fraction (Supplemental Table II). In the Cpc-PH subgroup only, there was a significant difference in cardiomyopathy between the high and low fibrosis-4 index groups ( Supplemental Table III ). Univariate analysis revealed that the fibrosis-4 index was a significant predictor for all-cause mortality in the Ipc-PH (HR 1.202, 95% CI 1.073-1.346, P = 0.001, Supplemental  Table IV ) and Cpc-PH (HR 1.475, 95% CI 1.059-2.053, P = 0.021) subgroups. The fibrosis-4 index was a significant predictor for cardiac death in the Ipc-PH subgroup (HR 1.247, 95% CI 1.065-1.461, P = 0.006), whereas it was not in the Cpc-PH subgroup (HR 1.186, 95% CI 0.745-1.889, P = 0.473).
Discussion
The present study, to the best of our knowledge, is the first report on the prognostic impact of the fibrosis-4 index on patients with PH-LHD. High fibrosis-4 index was revealed to be associated with high mortality in PH-LHD.
Left atrial pressure elevation due to LHD causes pulmonary hypertension. Lung vessels are subjected to pres-sure overload resulting from continuous elevation of left atrial pressure. This abnormality involves the pulmonary artery and leads to pulmonary hypertension, which elevates right-sided filling pressure and affects the hepatic venous system. Elevated hepatic venous pressure worsens the fibrosis-4 index. In addition, low cardiac output due to LHD causes low hepatic arterial flow, accelerating liver fibrosis. The PH-LHD patients with a higher fibrosis-4 index (2.323 to 14.339) had the lowest survival rate, which may be attributable to liver dysfunction due to elevated venous pressure and low hepatic arterial flow. Liver dysfunction is one reason for worse prognosis in the PH-LHD patients with a higher fibrosis-4 index.
The elevated fibrosis-4 index may have been caused by elevated venous pressure and low hepatic arterial flow. However, there were no significant differences in the mean right atrial pressure, mean pulmonary artery wedge pressure, or cardiac index among the PH-LHD patients regardless of fibrosis-4 index. This may be because we measured the fibrosis-4 index during the compensated phase of many heart failure patients in this study. PH-LHD patients with a higher fibrosis-4 index could experience worse hemodynamics during the decompensated phase of heart failure. Therefore, worse hemodynamics during the decompensated phase may have affected the prolonged elevation of the fibrosis-4 index during the compensated phase.
Hepatic cirrhosis is also encountered in patients with right heart failure, adult congenital heart disease, and severe tricuspid regurgitation, which cause chronically elevated venous pressure. The fibrosis-4 index might be a prognostic marker for patients with these conditions.
Other reasons for the poor prognosis of patients in the current study with a higher index were anemia and kidney dysfunction, which are well-known prognostic factors for heart failure, and are associated with severe liver fibrosis. 20, 21) Anemia and kidney dysfunction are significantly associated with a worse prognosis in heart failure. 22, 23) The association of anemia with heart failure and kidney disease is widely recognized as cardio-renalanemia syndrome, 24) and liver injury in heart failure is referred to as cardiohepatic syndrome. 25) Furthermore, anemia, kidney dysfunction, liver injury, and heart failure are closely correlated. PH-LHD patients with a higher fibrosis-4 index had worse kidney function and lower hemoglobin in the current study.
It has been reported that the fibrosis-4 index is correlated with the extent of fibrosis assessed by the METAVIR index from liver biopsy in chronic hepatitis C virusinfected patients. 18) Based on this previous study, PH-LHD patients with a lower fibrosis-4 index (0.335 to 1.381), a middle fibrosis-4 index (1.391 to 2.311), and a higher fibrosis-4 index (2.323 to 14.339) had a METAVIR index of 0 to 1, 2 to 3, and 4, respectively. 18) The extent of fibrosis advanced in PH-LHD patients with an increase in the fibrosis-4 index. Furthermore, using imaging modalities, the fibrosis-4 index is significantly associated with stiffness scores on Fibroscan in patients with nonalcoholic fatty liver disease. 26) The component factors of the fibrosis-4 index, which are aspartate transaminase, alanine transaminase, and platelet count, are varied in the acute setting of heart failure. We measured the fibrosis-4 index during the compensated phase of heart failure in this study, and suggested that the appropriate timing to check the fibrosis-4 index was indeed this phase.
The current pulmonary hypertension guidelines divide PH-LHD into Ipc-PH and Cpc-PH on the basis of 7 mmHg of diastolic pressure gradient and/or 3 Wood units of pulmonary vascular resistance. 17) We chose 2.6 Wood units as a subgroup analysis because the mean pulmonary vascular resistance in the subjects was 2.6 Wood units.
The present study has several limitations. First, the study population is a relatively small sample size. A larger study is needed to establish the usefulness of the fibrosis-4 index in patients with PH-LHD. We conducted a subgroup analysis, but not a multivariate Cox proportional analysis, since several confounding factors had multicollinearity, and the total event number of all-cause mortality was too small for a multivariate Cox proportional analysis. Second, we could not completely exclude the presence of liver disease, although documented liver disease was excluded in this study. Third, we did not use imaging modalities for liver fibrosis evaluation, which could have given us additional information regarding the association between liver status and the fibrosis-4 index.
In conclusion, the fibrosis-4 index is associated with the etiologies of heart failure, kidney function, anemia, and high mortality in PH-LHD patients.
